Previous Posts
- This blog has moved
- Avandia Given Positive Reviews Due to $$$$$?
- The FDA and Drug Approval
- J&J Planned Profit from Risky, Unapproved Uses of ...
- What Are the Different Classes of Drug Recalls?
- What Is the Difference Between Class Action and Mu...
- First Lawsuit for Avandia Filed In Santa Clara Cou...
- Our Involvement in the Yaz®/Yasmin® Litigation
- What Is An FDA Black Box Warning?
- What Is a Drug Recall?
Archives
- April 2008
- May 2008
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
- December 2009
- January 2010
- February 2010
- March 2010
- April 2010
Click Here to View
Our Other Site
Monday, August 3, 2009
FDA Approves New Type 2 Diabetes Drug
On Friday, the FDA approved a new drug, Onglyza, to treat Type 2 diabetes. Onglyza, a once-daily tablet for adults with Type 2 diabetes, is in a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors which stimulate the pancreas to make more insulin after eating a meal. People with Type 2 diabetes are either resistant to insulin or do not produce enough insulin to maintain normal blood sugar levels.
“Keeping blood sugar levels in adequate control is essential to the good health of the 24 million people in the United States with Type 2 diabetes,” said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “High blood sugar levels can cause blurry vision and excessive urination and eventually result in such serious conditions as kidney and eye disease.”
Approval of Onglyza was primarily based on the results of eight clinical trials. The application seeking FDA approval was submitted before December 2008 when the agency recommended that manufacturers of new diabetes drugs carefully design and evaluate their clinical trials for cardiovascular safety. Although Onglyza was not associated with an increased risk for cardiovascular events in patients who were mainly at low risk for these events, the FDA is requiring a post-market study that will specifically evaluate cardiovascular safety in a higher risk population.
The most common side effects observed with Onglyza are upper respiratory tract infection, urinary tract infection, and headache. Other side effects include allergic-like reactions such as rash and hives.
Onglyza is manufactured by Bristol-Myers Squibb Co. of Princeton, N.J., and marketed by Bristol-Myers and AstraZeneca Pharmaceuticals LP, of Wilmington, Delaware.
For more information see: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm174780.htm
Labels: blood sugar, clinical trials, diabetes type 2, FDA, Onglyza
posted by
Chavon Williams
at
1:20 PM
